Technical Analysis for LJPC - La Jolla Pharmaceutical Company

Grade Last Price % Change Price Change
grade F 6.13 -4.96% -0.32
LJPC closed down 4.96 percent on Friday, May 17, 2019, on 78 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical LJPC trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.96%
Wide Bands Range Expansion -4.96%
Oversold Stochastic Weakness -4.96%
Slingshot Bearish Bearish Swing Setup -6.70%
Lower Bollinger Band Walk Weakness -6.70%
Wide Bands Range Expansion -6.70%
Oversold Stochastic Weakness -6.70%
Lower Bollinger Band Walk Weakness -6.55%

Older signals for LJPC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. The company's products include GCS-100, a Phase-1/2 clinical trial drug used for the treatment of chronic kidney disease. It also provides LJPC-501, a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome. In addition, the company is developing LJPC-101, a subcutaneous formulation of GCS-100; LJPC-201, an oral galectin-3 inhibitor; and LJPC-301, a monoclonal antibody designed to neutralize galectin-3. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.
Biopharmaceutical Cancer Life Sciences Pharmaceutical Industry Medication Chronic Kidney Disease Peptide Hormones Proteins Lectins Galectin Galectin 3 Hepatorenal Syndrome
Is LJPC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 38.39
52 Week Low 5.01
Average Volume 535,044
200-Day Moving Average 12.9287
50-Day Moving Average 7.1562
20-Day Moving Average 7.3215
10-Day Moving Average 6.89
Average True Range 0.5046
ADX 28.18
+DI 19.3925
-DI 26.0346
Chandelier Exit (Long, 3 ATRs ) 7.0762
Chandelier Exit (Short, 3 ATRs ) 7.3438
Upper Bollinger Band 8.8004
Lower Bollinger Band 5.8426
Percent B (%b) 0.1
BandWidth 40.398825
MACD Line -0.2381
MACD Signal Line -0.0429
MACD Histogram -0.1952
Fundamentals Value
Market Cap 135.61 Million
Num Shares 22.1 Million
EPS -5.12
Price-to-Earnings (P/E) Ratio -1.20
Price-to-Sales 5475.91
Price-to-Book 5.28
PEG Ratio -0.48
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.69
Resistance 3 (R3) 6.75 6.62 6.59
Resistance 2 (R2) 6.62 6.48 6.59 6.56
Resistance 1 (R1) 6.38 6.39 6.32 6.32 6.53
Pivot Point 6.25 6.25 6.22 6.22 6.25
Support 1 (S1) 6.01 6.11 5.95 5.95 5.73
Support 2 (S2) 5.88 6.02 5.85 5.70
Support 3 (S3) 5.64 5.88 5.67
Support 4 (S4) 5.58